2016

Van Hemelrijck M, Garmo H, Lindhagen L, Bratt O, Stattin P, Adolfsson J. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer, Eur Urol. Nov 2 2016. Sammanfattning

Häggström C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg L, Gudbjörnsdottir S, Garmo H, Stattin P. Prospective study of Type 2 Diabetes Mellitus, anti-diabetic drugs, and risk of prostate cancer, Int J Cancer. Oct 22 2016. Sammanfattning

Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P. Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden, JAMA Oncol. Oct 20 2016. Sammanfattning

Tomic K, Westerberg M, Robinson D, Garmo H, Stattin P. Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden, Acta Oncol. Oct 17 2016. Sammanfattning

Wilson KM, Markt SC, Fang F, Nordenvall C, Rider JR, Ye W, Adami HO, Stattin P, Nyrén O, Mucci LA. Snus use, smoking and survival among prostate cancer patients, Int J Cancer. Sep 1 2016. Sammanfattning

Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M. Association between duration and type of Androgen Deprivation Therapy and risk of diabetes in men with prostate cancer, Int J Cancer. Aug 25 2016. Sammanfattning

Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, Stattin P. Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy, J Surg Oncol. Aug 11 2016. Sammanfattning

Loeb S, Stattin P. Further Evidence against a Causal Association between Erectile Dysfunction Drugs and Melanoma, Eur Urol. Jul 16 2016. Sammanfattning

Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study, J Natl Cancer Inst. Jul 10 2016. Sammanfattning, Fulltext

Stattin P, Sandin F, Thomsen FB, Garmo H, Robinson D, Lissbrant IF, Jonsson H, Bratt O. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study, Eur Urol. Jul 29 2016. Sammanfattning

Thorstenson A, Garmo H, Adolfsson J, Bratt O. Cancer-specific mortality in men diagnosed with prostate cancer before age 50 years, a nationwide population-based study, J Urol. Jun 17 2016. Sammanfattning

Fridriksson JÖ, Folkvaljon Y, Nilsson P, Robinson D, Franck-Lissbrant I, Ehdaie B, Eastham JA, Widmark A, Karlsson CT, Stattin P. Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study, Scand J Urol. Jun 22:1-8 2016. Sammanfattning

Bjartell A, Bottai M, Persson J, Bratt O, Damber JE, Stattin P, Akre O. Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort, Scand J Urol. May 18 2016. Sammanfattning

Stattin P. Svenska kvalitetsregister slår hål på larmrapporter – Register med stora studiepopulationer ger liten risk för fynd baserade på slump eller förväxling, Läkartidningen Apr 20 2016. Sammanfattning, Artikel

Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, Stattin P. Immediate versus delayed prostatectomy: Nationwide population-based study, Scand J Urol. Apr 12 2016. Sammanfattning

Arthur R, Møller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, Lambe M, Hammar N, Walldius G, Robinson D, Jungner I, Hemelrijck MV. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories, Cancer Med. Feb 29 2016. Sammanfattning

Lundström KJ, Folkvaljon Y, Loeb S, Axelson AB, Stattin P, Nordin P. Small bowel obstruction and abdominal pain after robotic versus open radical prostatectomy, Scand J Urol. Mar 3 2016. Sammanfattning

Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L. The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012, BJU Int. Feb 25 2016. Sammanfattning

Plym A, Voss M, Stattin P, Lambe M. Assessing Work Disability After Radical Prostatectomy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.01.005: The Challenge of Assessing Work Disability, Eur Urol. Feb 9, 2016. Sammanfattning, Fulltext

Loeb S, Lambe M, Stattin P. Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D. F. Penson J Urol 2015;194:1710-1711, J Urol. Jan 16 2016. Sammanfattning

Plym A, Chiesa F, Voss M, Holmberg L, Johansson E, Stattin P, Lambe M. Work Disability After Robot-assisted or Open Radical Prostatectomy: A Nationwide, Population-based Study, Eur Urol. Jan 15 2016 Sammanfattning, Fulltext

Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment, Eur Urol. Dec 29 2015 Sammanfattning

Björklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, Stattin P, Akre O. Ninety-Day Postoperative Mortality after Robot-assisted Laparoscopic Prostatectomy and Retropubic Radical Prostatectomy. Nation-wide population-based study, BJU Int. Jan 13 2016 Sammanfattning

Comments are closed.